Cooperative hospitals: Hebei Yanda Lu Daopei Hospital, Hebei Medical University Second Hospital, Wuhan Tongji Hospital, Tianjin Blood Research Institute, Hebei Medical University Fourth Hospital, Peking University People's Hospital, etc.

As of April 2022, Senlang Bio has completed a total of 721 patient cell reinfusions in 29 clinical research bases. The clinical effect is the most direct way to verify the function of the product, and the close clinical cooperation relationship has created favorable conditions for the trial of the company's new products.

Through clinical trial cooperation with a number of large hospitals, the company has successfully established more than ten CAR-T preparation and clinical application mechanisms that can be applied to leukemia, lymphoma, multiple myeloma and other indications.

The CAR-T series of products created by Senlang Bio are at the world's leading level in increasing the number of memory T cells, improving the virus transfection rate, and optimizing the CAR-T structure to reduce immune attacks.